Philips Leads European Patent Rankings in Medical Technology for 2025
On Tuesday, Philips announced its top ranking among medical technology companies at the European Patent Office (EPO) in 2025. The Dutch group filed 1,289 patent applications with the EPO last year, confirming its leadership in medical sector innovation.
Philips secured the top spot among medical technology companies in the EPO's 2025 technology dashboard. The group submitted 1,289 patent applications to the organization in 2025. According to the press release, Philips is also the leading Dutch patent applicant at the EPO. Medical technology is the most significant field for Dutch patent applications submitted to the EPO.
Innovative Solutions Integrating Hardware, Software, Data, and AI
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Philips states that its solutions are based on an approach that integrates hardware, software, data, and artificial intelligence to address clinical, operational, and everyday health challenges. The company noted that its innovations improved the lives of 2 billion people in 2025. Philips has set a goal to enhance the lives of 2.5 billion people annually by 2030, including 400 million individuals in medically underserved communities.
SectorSanté · Technologie · Dispositifs médicaux›Équipements Médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 3.9MD€
Free cash flow: 28M€
Guidance from the release
Nous avons délivré un bon départ en 2026.
Bonne performance au T1, croissance des ventes et des marges.
Risks mentioned
Impact des tarifs et inflation des coûts sur les marges.
Environnement macroéconomique incertain impactant les performances.
Opportunities identified
Croissance des ventes comparables de 4% dans tous les segments.
Augmentation du carnet de commandes grâce à des innovations.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
